Aug 13, 2026 07:30AM
Jun 3, 2026 07:03AM
Jun 3, 2026 07:00AM
May 14, 2026 07:05AM
Apr 28, 2026 08:01AM
Apr 28, 2026 08:00AM
Apr 28, 2026 08:00AM Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Apr 28, 2026 08:00AM
Apr 14, 2026 04:30PM
Apr 1, 2026 06:58AM
Mar 23, 2026 01:54PM
Mar 23, 2026 01:53PM
Mar 23, 2026 07:30AM
Mar 23, 2026 07:30AM Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Jan 12, 2026 08:10AM
Jan 12, 2026 08:00AM
Jan 12, 2026 07:31AM
Jan 12, 2026 07:30AM
Nov 10, 2025 07:30AM
Oct 27, 2025 07:00AM
Aug 8, 2025 08:33AM Cabaletta Bio Inc. (CABA) PT Lowered to $15 at Guggenheim
Aug 7, 2025 04:52PM
Aug 7, 2025 07:30AM
Jun 27, 2025 11:31AM
Jun 11, 2025 06:01AM
Jun 11, 2025 06:00AM
Jun 11, 2025 06:00AM
May 15, 2025 07:00AM Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
Mar 31, 2025 07:00AM
Feb 18, 2025 10:21AM
Feb 18, 2025 07:03AM
Feb 18, 2025 07:00AM
Jan 13, 2025 08:00AM
Nov 18, 2024 07:00AM
Nov 18, 2024 07:00AM Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Nov 14, 2024 01:47PM
Nov 14, 2024 07:00AM
May 15, 2024 07:00AM
Mar 21, 2024 07:00AM
Mar 20, 2024 07:00AM
Mar 20, 2024 07:00AM
Feb 1, 2024 04:30PM Cabaletta Bio (CABA) Granted FDA Orphan Drug Designation to CABA-201
Feb 1, 2024 04:30PM
Jan 8, 2024 07:02AM
Jan 8, 2024 07:00AM
Nov 9, 2023 07:00AM
Nov 6, 2023 07:00AM
Nov 6, 2023 07:00AM
Oct 2, 2023 07:07AM Cabaletta Bio (CABA) Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
Oct 2, 2023 07:00AM

329,910 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All